HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
Pediatric sepsis is "an aggressive and unrelenting adversary that knows neither geographic nor demographic bounds," writes Chris DeRienzo, M.D., AHA’s senior…
Headline
Centers for Disease Control and Prevention and state and territorial public health officials Friday met to discuss preparedness planning for bird flu after one…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
AHA is looking forward to spring and March Madness in its latest social media toolkit for hospitals’ and health systems’ use to promote vaccination against the…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
The Centers for Disease Control and Prevention has released a five-part webinar series on its Hospital Sepsis Program Core Elements, which offer guidance to…